IDEAYA Biosciences (NASDAQ:IDYA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares IDEAYA Biosciences and Calithera Biosciences' gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| IDEAYA Biosciences | N/A | N/A | $-41,970,000.00 | ($3.36) | -5.52 |
| Calithera Biosciences | $22.25 million | 6.76 | $-89,860,000.00 | ($1.90) | -1.08 |
IDEAYA Biosciences has higher earnings, but lower revenue than Calithera Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares IDEAYA Biosciences and Calithera Biosciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| IDEAYA Biosciences | N/A | -28.83% | -22.92% |
| Calithera Biosciences | N/A | -66.64% | -56.60% |
Volatility & Risk
IDEAYA Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for IDEAYA Biosciences and Calithera Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| IDEAYA Biosciences | 0 | 0 | 6 | 0 | 3.00 |
| Calithera Biosciences | 0 | 1 | 3 | 0 | 2.75 |
IDEAYA Biosciences presently has a consensus price target of $31.4444, indicating a potential upside of 69.42%. Calithera Biosciences has a consensus price target of $5.20, indicating a potential upside of 153.66%. Given Calithera Biosciences' higher possible upside, analysts plainly believe Calithera Biosciences is more favorable than IDEAYA Biosciences.
Insider and Institutional Ownership
62.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are owned by institutional investors. 20.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 11.9% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
IDEAYA Biosciences beats Calithera Biosciences on 7 of the 12 factors compared between the two stocks.
